" class="no-js "lang="en-US"> 3Z - Medtech Alert
Thursday, March 30, 2023

Breaking News

Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Implantica Launches RefluxStop™ in Italy Granular Therapeutics to Accelerate Development of Next-Generation Pipeline for Treating Mast Cell Driven Diseases Xeris Biopharma Appoints Ricki Fairley to Board of Directors AskBio to Present Phase 1b Results Investigating AB-1005 as Treatment for Parkinson’s Disease New Imaging Method for Evaluating Transport of Oxygen to Blood Cells
3Z | Pharmtech Focus

3Z

About 3Z

3Z
3Z incorporates the latest advances in disease modeling and behavioral genetics to discover novel drug candidates for CNS disorders.

Related Story

Drug Development

 3Z Closes $2 Million Funding for Preclinical Development of Novel ADHD and Insomnia Therapeutics Identified by 3Z´s Zebrafish Drug Discovery Platform | Pharmtech Focus

3Z Closes $2 Million Funding for Preclinical Development of Novel ADHD and Insomnia Therapeutics Identified by 3Z´s Zebrafish Drug Discovery Platform

June 21 2022

3Z, a Reykjavik based drug discovery company is pleased to announce the closure of a $2 million funding round […]